keyword
MENU ▼
Read by QxMD icon Read
search

pharmacoeconomic

keyword
https://www.readbyqxmd.com/read/29241885/cost-effectiveness-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-for-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-in-the-netherlands-a-country-adaptation-analysis-under-the-former-and-current-dutch-pharmacoeconomic
#1
Isaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, Jolanda M A Koenders, Gerard C M Linssen, Joan G Meeder, Maureen P M H Rutten-van Mölken
OBJECTIVES: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29241341/abaloparatide-review-of-a-next-generation-parathyroid-hormone-agonist
#2
Eric G Boyce, Yvonne Mai, Christopher Pham
OBJECTIVE: To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis. DATA SOURCES: PubMed (1966 to October 2017), Clinicaltrials.gov (October 2017), and Scopus (1970 to October 2017) were searched using abaloparatide, Tymlos, BA058, PTHrP 1-34 analog, and parathyroid hormone-related peptide 1-34 analog. STUDY SELECTION AND DATA EXTRACTION: Human studies published in peer-reviewed publications in English were the primary sources for efficacy, safety, and economic data...
December 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29233328/pharmacoeconomics-education-in-yemen
#3
Yaser Mohammed Al-Worafi
No abstract text is available yet for this article.
September 2017: Currents in Pharmacy Teaching & Learning
https://www.readbyqxmd.com/read/29232913/pharmacoeconomic-analysis-of-drugs-used-in-the-treatment-of-pneumonia-in-paediatric-population-in-a-tertiary-care-hospital-in-india-a-cost-of-illness-study
#4
Lekha Saha, Sharonjeet Kaur, Pratibha Khosla, Sweta Kumari, Alka Rani
AIMS AND OBJECTIVES: The cost of antibiotic therapy for the treatment of pneumonia in the inpatient paediatric population can have a major impact on the healthcare expenditure. We planned to assess the direct and indirect costs of diagnosis and medical treatment of paediatric patients with community acquired pneumonia who are hospitalized in a tertiary care hospital in India. METHODS: 125 children with a diagnosis of pneumonia who were admitted to the inpatient department of a paediatric hospital receiving antibiotic treatment were observed...
December 11, 2017: Medical Sciences: Open Access Journal
https://www.readbyqxmd.com/read/29220854/inhibitors-in-hemophilia-a-a-pharmacoeconomic-perspective
#5
Andrea Messori
No abstract text is available yet for this article.
December 8, 2017: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/29206096/danish-translation-of-the-foot-and-ankle-outcome-score
#6
Peter Larsen, Anne Marie Boe, Annika B Iyer, Rasmus Elsøe
INTRODUCTION: The Foot and Ankle Outcome Score (FOAS) is a standardized instrument used to report on injury-specific clinical status following foot- and ankle-related problems. The primary aim of this study was to translate and conduct a cross-cultural adaptation of the FAOS into a Danish setting, including testing absolute agreement and the test-retest reliability of the questionnaire. METHODS: Translation of the FAOS questionnaire was 
carried out according to the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-
Reported Outcomes Measures: report of the Society for Pharmacoeconomics and Outcomes Research Task Force 
for Translation and Cultural Adaptation...
December 2017: Danish Medical Journal
https://www.readbyqxmd.com/read/29202676/precision-medicine-for-hiv-where-are-we
#7
Jessica Cusato, Sarah Allegra, Amedeo De Nicolò, Andrea Calcagno, Antonio D'Avolio
To date, antiretroviral therapy is highly effective in HIV-affected patients, but the individualization of such a life-long therapy may be advised. This review briefly summarizes the main factors involved in the potential personalization of antiretroviral treatment. Relevant articles in English were identified by PubMed and recent congresses' abstracts. Foremost influences concerning pharmacodynamics, therapeutic drug monitoring, pharmacogenetics, comorbidities, immune recovery and viral characteristics affecting the healthcare of HIV-positive patients are listed here...
December 5, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/29200882/early-intervention-in-the-management-of-pulmonary-arterial-hypertension-clinical-and-economic-outcomes
#8
REVIEW
Charles D Burger, Mohamedanwar Ghandour, Divya Padmanabhan Menon, Haytham Helmi, Raymond L Benza
Pulmonary arterial hypertension (PAH) has a high morbidity rate and is fatal if left untreated. Increasing evidence supports early intervention, possibly with initial combination therapy. PAH-specific pharmaceuticals, however, are expensive and may have serious adverse effects, particularly when used in combination. The currently dynamic health care economy reinforces the need for a review of early intervention from both outcomes and economic perspectives. We aimed to review the clinical and economic impact of PAH therapy, particularly examining drug cost, hospitalization burden, and health care economics impact, and the effect of early intervention on clinical outcomes...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29189600/pharmacoeconomic-and-associated-cost-savings-among-women-who-were-prescribed-systemic-conjugated-estrogens-therapy-compared-with-those-without-menopausal-therapy
#9
Wing Yu Tang, Dale Grothe, Allison Keshishian, Diana Morgenstern, Seema Haider
OBJECTIVE: To explore changes in healthcare costs among postmenopausal women in a commercial population who were prescribed conjugated estrogens for menopausal symptoms. METHODS: Using the MarketScan dataset from April 1, 2008 through September 30, 2012, postmenopausal women aged ≥45 years, who were prescribed conjugated estrogen tablets (Premarin), were identified. A comparative cohort of postmenopausal women with vasomotor symptoms without any menopause therapy was also identified...
November 20, 2017: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29185089/pharmacoeconomic-evaluation-of-micafungin-versus-caspofungin-as-definitive-therapy-for-candidaemia-and-invasive-candidiasis-ic-in-turkey
#10
C F Neoh, E Senol, A Kara, E C Dinleyici, S J Turner, D C M Kong
Micafungin was shown to be as efficacious as caspofungin in treating patients with candidaemia and invasive candidiasis (IC). However, it remains unknown if micafungin or caspofungin is a cost-effective definitive therapy for candidaemia and IC in Turkey. The present study aimed to determine the economic impact of using micafungin versus caspofungin for treatment of candidaemia and IC in the Turkish setting. A decision analytic model was constructed and was populated with data (i.e. transition probabilities, duration of initial antifungal treatment, reasons for treatment failure, percentage of patients who stepped down to oral fluconazole, and duration on oral fluconazole) obtained from a published randomised clinical trial...
November 28, 2017: European Journal of Clinical Microbiology & Infectious Diseases
https://www.readbyqxmd.com/read/29184741/psychometric-validation-of-the-body-q-in-danish-patients-undergoing-weight-loss-and-body-contouring-surgery
#11
Lotte Poulsen, Anne Klassen, Michael Rose, Kirsten K Roessler, Claus Bogh Juhl, René Klinkby Støving, Stefan Cano, Jens Ahm Sørensen
Background: A well-developed patient-reported outcome instrument is needed for use in Danish bariatric and body contouring patients. The BODY-Q is designed to measure changes in important patient outcomes over the entire patient journey, from obesity to post-body contouring surgery. The current study aims to psychometrically validate the BODY-Q for use in Danish patients. Methods: The process consisted of 3 stages: translation and linguistic validation, field-test, and data analysis...
October 2017: Plastic and Reconstructive Surgery. Global Open
https://www.readbyqxmd.com/read/29179776/translation-and-cultural-adaptation-of-the-cleft-q-for-use-in-colombia-chile-and-spain
#12
Elena Tsangaris, Karen W Y Wong Riff, Federico Vargas, Mirta Palomares Aguilera, Macarena Miranda Alarcón, Asteria Albert Cazalla, Lehana Thabane, Achilleas Thoma, Anne F Klassen
BACKGROUND: Cleft lip and/or palate (CL/P) is a common congenital craniofacial anomaly that may negatively affect an individual's appearance, health-related quality of life, or speech. In Spain, Colombia, and Chile the overall prevalence of CL/P ranges from 0.53 to 1.59 cases per 1000 live births. Currently, there is no patient-reported outcome (PRO) instrument that is specific for patients with CL/P. The CLEFT-Q is a new PRO instrument developed to measure outcomes of treatment in patients 8 to 29 years of age with CL/P...
November 28, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/29149148/current-impact-and-application-of-abuse-deterrent-opioid-formulations-in-clinical-practice
#13
Ya-Han Lee, Daniel L Brown, Hsiang-Yin Chen
BACKGROUND: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. OBJECTIVE: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. METHODS: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations...
November 2017: Pain Physician
https://www.readbyqxmd.com/read/29108767/biologics-in-the-treatment-of-severe-asthma
#14
REVIEW
S Quirce, E Phillips-Angles, J Domínguez-Ortega, P Barranco
Severe asthma is defined as asthma which requires treatment with high dose inhaled corticosteroids and with a second controller drug to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy. Patients with uncontrolled severe asthma require additional treatment options as add-on therapy, including biologics. Biologic therapies in asthma are designed to block key immune regulators, such as IgE, or certain pro-inflammatory cytokines, e.g. interleukin (IL)-5, IL-4, IL-13 or IL-17...
December 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29073991/concept-of-combining-cost-effectiveness-analysis-and-budget-impact-analysis-in-health-care-decision-making
#15
Roza Ismailovna Yagudina, Andrey Urievich Kulikov, Vjacheslav Gennadievich Serpik, Dzhumber Tengizovich Ugrekhelidze
OBJECTIVES: The objective of this study is to cover the ways of solving the problem of understanding the results of two key methods of pharmacoeconomic analysis - budget impact and cost-effectiveness. It is important to note that pharmacoeconomic assessment based on this evidence often has controversial character. The results of one type of analysis can characterize assessed health technology favorably, and the results of other critically. Pharmacoeconomic evidence is often a crucial part of decision-making in healthcare, that's why clear understanding of combination of this two types of analysis is highly in demand...
September 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29073981/applying-multi-criteria-decision-analysis-mcda-simple-scoring-as-an-evidence-based-hta-methodology-for-evaluating-off-patent-pharmaceuticals-opps-in-emerging-markets
#16
Diana Brixner, Nikos Maniadakis, Zoltán Kaló, Shanlian Hu, Jie Shen, Kalman Wijaya
Off-patent pharmaceuticals (OPPs) represent more than 60% of the pharmaceutical market in many emerging countries, where they are frequently evaluated primarily on cost rather than with health technology assessment. OPPs are assumed to be identical to the originators. Branded and unbranded generic versions can, however, vary from the originator in active pharmaceutical ingredients, dosage, consistency formulation, excipients, manufacturing processes, and distribution, for example. These variables can alter the efficacy and safety of the product, negatively impacting both the anticipated cost savings and the population's health...
September 2017: Value in Health Regional Issues
https://www.readbyqxmd.com/read/29066972/adapting-pharmacoeconomics-to-shape-efficient-health-systems-en-route-to-uhc-lessons-from-two-continents
#17
Jacqui Miot, Michael Thiede
Background: Pharmacoeconomics is receiving increasing attention globally as a set of tools ensuring efficient use of resources in health systems, albeit with different applications depending on the contextual, cultural and development stages of each country. The factors guiding design, implementation and optimisation of pharmacoeconomics as a steering tool under the universal health coverage paradigm are explored using case studies of Germany and South Africa. Findings: German social health insurance is subject to the efficiency precept...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29052427/the-joint-ispor-ispe-special-task-force-on-real-world-evidence-in-health-care-decision-making-an-interview-with-marc-berger
#18
Marc L Berger
Marc L Berger, MD, is a retired, part-time consultant. He recently became Chair of the Real World Evidence Advisory Board for SHYFT Analytics. Over a 25-year industry career, Marc has held senior-level positions at Pfizer, Inc., OptumInsight, Eli Lilly and Company, and Merck & Co., Inc. His professional activities have included serving on committees for Center for Medicare and Medicaid Services (CMS), Agency for Healthcare Research and Quality (AHRQ), Patient-Centered Outcomes Research Institute (PCORI), the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Drug Information Association (DIA), and the editorial advisory boards of several journals...
October 20, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29052155/special-edition-on-utility-measurement-pharmacoeconomics
#19
EDITORIAL
Andrew Lloyd
No abstract text is available yet for this article.
October 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29044643/fidaxomicin-versus-vancomycin-as-a-first-line-treatment-for-clostridium-difficile-associated-diarrhea-cdad-in-specific-patient-populations-a-pharmacoeconomic-evaluation
#20
Kelly R Reveles, Jennifer L Backo, Frank A Corvino, Marko Zivkovic, Kelly C Broderick
OBJECTIVES: The reduction in recurrent Clostridium difficile-associated diarrhea (CDAD) with fidaxomicin therapy may reduce hospital readmissions and lead to lower overall CDAD costs. However, studies assessing the cost-effectiveness of fidaxomicin as first-line therapy from the United States (US) hospital perspective are lacking. This study evaluated the costs associated with utilizing fidaxomicin or vancomycin as a first-line therapy for CDAD in specific patient populations from a US hospital perspective...
October 17, 2017: Pharmacotherapy
keyword
keyword
9163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"